Span­ish VC preps launch for €100M fund with an em­pha­sis on ad­vanced ther­a­pies

In­vi­vo is tar­get­ing €100 mil­lion ($108.7 mil­lion) for its third fund, with an eye on Eu­ro­pean ear­ly-stage biotechs with ad­vanced ther­a­pies such as cell ther­a­py, gene ther­a­py and syn­thet­ic bi­ol­o­gy.

The Barcelona-based VC has helped steer some no­table ex­its for its port­fo­lio com­pa­nies, in­clud­ing Gen­fit’s 2022 ac­qui­si­tion of Swiss or­phan drug com­pa­ny Ver­san­tis for CHF40 mil­lion up­front and Vi­for Phar­ma’s 2021 pur­chase of Pal­ma, Spain-based car­dio-re­nal com­pa­ny San­i­fit Ther­a­peu­tics for €205 mil­lion up­front.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER